跳至主要内容
临床试验/NCT05649709
NCT05649709已完成4 期

Fourteen-day Vonoprazan and Low-or High-dose Amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection: a Prospective, Multi-centers, Open-labeled, Non-inferior, Randomized Clinical Study

The First Affiliated Hospital of Nanchang University1 个研究点 分布在 1 个国家目标入组 504 人开始时间: 2023年2月13日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
504
试验地点
1
主要终点
The efficacy of VA dual therapy

研究概览

简要总结

Our previous study included 119 Helicobacter pylori(H. pylori)-infected Chinese patients without previous eradication history who were randomized to low-or high-dose amoxicillin-vonoprazan regimens consisting of amoxicillin 1 gram either b.i.d. or t.i.d plus vonoprazan 20 mg b.i.d for 7 or 10 days. Neither 7-or 10-day VA dual therapy with either b.i.d. or t.i.d. amoxicillin achieved satisfied efficacy (i.e., <90%) when given as first-line treatment for H. pylori infection. This study evaluated the efficacy and safety of low-and high-dose amoxicillin-vonoprazan dual therapy for 14 days as first-line treatment for H. pylori in China.

详细描述

Upper gastrointestinal endoscopy examinations were performed for all participants and biopsies from gastric antrum and body were obtained. All the collected gastric biopsy specimens were sent to Jiangxi Provincial Key Laboratory of Digestive Diseases, First Affiliated Hospital of Nanchang University for susceptibility testing of antibiotics. The minimum inhibitory concentrations of antibiotics (amoxicillin, metronidazole, clarithromycin, levofloxacin and tetracycline) were determined by E-test. The inhibition zone for furazolidone was determined by the Kirby-Bauer disc diffusion method. Detailed procedure for detecting antibiotics resistance were consistent with our previous study. A strain was considered as resistant if minimum inhibitory concentration >0.125 μg/mL for amoxicillin, >8 μg/mL for metronidazole, ≥1 μg/mL for clarithromycin, >2 μg/mL for levofloxacin, ≥2 μg/mL for tetracycline, the inhibition zone was ≤7mm for furazolidone.

The detailed demographics and characteristics (sex, age, nationality, height, weight, education status, dwelling area, history of smoking and alcohol etc.) were recorded. The treatment-related adverse events (TEAEs) were recorded. We defined adherence as good if the participants took ≥80% drugs of the regimen during the consecutive 14 days. The H. pylori status after therapy was evaluated by ¹³C-UBT at least 6 weeks after completion of treatment. Proton pump inhibitors and antibiotics were stopped at least 2 and 4 weeks before ¹³C-UBT, respectively.

The stool samples were collected at baseline (before treatment), week 2 (after eradication) and week 8-10 (confirmation of H. pylori status). We sent the stool samples from subjects with successful eradication for metagenome DNA extraction and shotgun sequencing to avoid the influence of H. pylori eradication failure on gut microbiota. Briefly, OMEGA Mag-Bind Soil DNA Kit (Omega Bio-Tek, Norcross, GA, USA) was used to extract total microbial genomic DNA samples. Metagenome shotgun sequencing libraries from extracted microbial DNA was constructed by Illumina TruSeq Nano DNA LT Library Preparation Kit, which was then sequenced by Illumina NovaSeq platform (Illumina, USA) with PE150 strategy at Personal Biotechnology Co., Ltd. (Shanghai, China).

Raw sequencing reads were subjected to processing to yield quality-filtered reads suitable for further analysis, including removal of adapter and low-quality reads. Subsequently, minimap2 was utilized to align reads to the host genome of human and eliminate host contamination. Gene prediction was carried out on the generated contigs from each sample, whose translated protein sequences were subsequently pooled and clustered using mmseqs2. The lowest common ancestor taxonomy of the non-redundant genes was ascertained using mmseqs2 in "taxonomy" mode, by aligning them against a customized database comprising protein sequences of bacteria from GTDB (release 207: https://data.ace.uq.edu.au/public/gtdb/data/releases/), fungi from NCBI-nr (https://ftp.ncbi.nlm.nih.gov/blast/db/FASTA/), and viruses from RVDB (version 24.1: https://rvdb.dbi.udel.edu/download/). In order to assess the abundance of genes, high-quality reads from each sample were mapped onto the contigs using minimap2 and read counts were computed using htseq. Abundance values in metagenomes were normalized using copies per kilobase per million mapped reads. Clean high-quality reads were processed and profiled with ARGs-OAP (version 2.0) by querying against the SARG (version 3.0-F) database, which is a structural antimicrobial resistance genes database containing 32 types and 2842 subtypes of antibiotic resistance genes. In order to perform the quantification and downstream analysis of diversity indices, resistome profiling, and prevalence ranking, the abundance of antibiotic resistance genes at type and subtype level were normalised to the number of 16S rRNA genes.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Consecutive H. pylori-infected subjects ages from 18 to 70 without eradication history

排除标准

  • allergy to amoxicillin or vonoprazan;
  • acute upper gastrointestinal bleeding, gastric cancer or other tumors, Zollinger-Ellison syndrome, history of gastric surgery;
  • serious illness including neurological, cardiovascular, pulmonary, hepatic, renal, metabolic, gastrointestinal, urological, endocrinological or hematological disorders;
  • pregnancy or breast feeding;
  • proton pump inhibitors and antibiotics use within one month;
  • not willing to participate in the study

研究组 & 干预措施

vonoprazan and low-dose amoxicillin dual therapy

Experimental

1000 mg amoxicillin capsules twice daily and 20 mg vonoprazan Fumarate Tablets twice daily for 14 days

干预措施: L-VA dual therapy (Drug)

vonoprazan and high-dose amoxicillin dual therapy

Active Comparator

1000mg amoxicillin capsules three times daily and 20mg vonoprazan Fumarate Tablets twice daily for 14 days

干预措施: H-VA dual therapy (Drug)

结局指标

主要结局

The efficacy of VA dual therapy

时间窗: 6-8 weeks after treatment

The confirmation of H. pylori status was evaluated by urea breath test

次要结局

  • compliance(1 day after eradication)
  • the alteration of gut microbiota(before eradication,1 day after eradication and confirmation(6-8 weeks after treatment))
  • treatment-emergent adverse events(1 day after eradication)
  • resistance of antibiotics(before the eradication)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Iv Nonghua

Professor

The First Affiliated Hospital of Nanchang University

研究点 (1)

Loading locations...

相似试验